Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial
- Resource Type
- Article
- Source
- In
Lung Cancer April 2023 178:151-156 - Subject
- Language
- ISSN
- 0169-5002